Jiangxi Fushine Pharmaceutical Co., Ltd. (SHE: 300497), a Chinese pharmaceutical company, has announced that its subsidiary, LinkChem, intends to conduct an initial public offering (IPO) on the Hong Kong Stock Exchange. At this stage, no further details regarding the IPO have been disclosed.
Established in 2011 and headquartered in Shanghai, LinkChem specializes in organic synthesis chemistry. The company offers a suite of professional technical services and is engaged in the commercial production of small molecule pharmaceutical raw materials, characteristic small molecule intermediates, and special material monomers. These products and services are provided to renowned pharmaceutical, new material, and energy enterprises both domestically and internationally.
In 2023, LinkChem achieved revenues of RMB 485 million and recorded a net profit of RMB 136 million, demonstrating strong financial performance.- Flcube.com
